Clinical trials
Blindness, Cortical trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 1 |
| 2026 | 9 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Recruiting | 10 |
| Not yet recruiting | 7 |
| Unknown status | 4 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Alabama at Birmingham | 3 |
| Georgetown University | 2 |
| Universitaire Ziekenhuizen KU Leuven | 2 |
| Wake Forest University Health Sciences | 2 |
| Abant Izzet Baysal University | 1 |
| Balton Sp.zo.o. | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| Bydgoszcz University of Science and Technology | 1 |
| Centre Hospitalier Universitaire Dijon | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Blindness, Cortical | 34 |
| Hemianopsia | 6 |
| Cerebral Palsy | 5 |
| Macular Degeneration | 5 |
| Vision Disorders | 5 |
| Scotoma | 4 |
| Stroke | 3 |
| Blindness | 2 |
| Brain Injuries, Traumatic | 2 |
| Brain Neoplasms | 2 |
Trials
Showing 26 to 34 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.